|
KMID : 0364320210460010007
|
|
Journal of East-West Medicine
2021 Volume.46 No. 1 p.7 ~ p.23
|
|
|
Effects of 2.5 hr-interval seven-day repeated oral combination treatment of Gamisoyo-san on the pharmacokinetics profiles of tamoxifen
|
|
Kang Hyun-Gu
Park Soo-Jin
Choi Seong-Hun
Ku Sae-Kwang
|
|
|
Abstract
|
|
|
Objectives : This study aims to elucidate the possible effects on the pharmacokinetics (PK) of tamoxifen after 7-day repeated oral co-administration of Gamisoyo-san (GMSYS) with 2.5 hr-intervals, as a process of the comprehensive and integrative medicine, combination therapy of tamoxifen with GMSYS to achieve synergic pharmacodynamics and reduce toxicity in breast cancer patients.
Materials and methods : Two point five hrs after treatment of tamoxifen 50 mg/kg, GMSYS 100 mg/kg was administered, once a day for 7 days. In tamoxifen single treated rats, 50 mg/kg of tamoxifen was orally administered and 2.5 hrs after treatment, distilled water 5 ml/kg was orally administered, instead of GMSYS solutions. The plasma were collected at 30 min before administration, 30 min, 1, 2, 3, 4, 6, 8 and 24 hrs after end of last 7th tamoxifen treatment, and plasma concentrations of tamoxifen were analyzed using liquid chromatographic and mass-spectroscopic system. PK of tamoxifen (Tmax, Cmax, AUC, ti/2 and MRTinf) after co-administration of GMSYS 100 mg/kg and tamoxifen 50 mg/kg, was analysis as compared with tamoxifen single administered rats using noncompartmental PK data analyzer programs. Each tamoxifen or GMSYS was orally administered, in a volume of 5 m/kg, dissolved in distilled water, once a day for 7 days.
Results : GMSYS did not influence on the plasma concentrations of tamoxifen as compared with tamoxifen single treated rats and accordingly, no significant changes on the pharmacokinetics profiles, Tmax, Cmax, AUC, t1/2 and MRTinf were observed as compared with tamoxifen single treated rats, when tamoxifen 50 mg/kg and GMSYS 100 mg/kg 2.5 hr-interval co-administered, once aday for 7 days.
Conclusion : Based on the results, co-administration of GMSYS with 2.5 hr-intervals did not critically influenced on the absorption and excretion of tamoxifen, the oral bioavailability. Hence, 2.5 hr-interval co-administration is considered as suitable regime of GMSYS and tamoxifen to achieve synergic pharmacodynamics and reduce toxicity for breast cancer patients as comprehensive and integrative therapy, and further pharmacodynamic studies should be conducted along with tamoxifen and GMSYS 2.5 hr-interval co-administration.
|
|
|
KEYWORD
|
|
|
Tamoxifen, Gamisoyo-san, Pharmacokinetics, 2 5 hr-interval 7 day-repeated oral administration, Rat , Combination
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|